Zhiwei Feng

Prof. Zhiwei Feng


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Advanced Science
Verified
Journal Article
Open access
ZSZe‐Yu Sun
Ze‐Yu Sun
JYJiayi Yuan
Jiayi Yuan
DJDivya Jaiswal
Divya Jaiswal
JGJingxuan Ge
Jingxuan Ge
TLTianjian Liang
Tianjian Liang
ZFZhiwei Feng
Zhiwei Feng
Antibodies are crucial for medical applications, yet traditional methods for designing sequences are inefficient. This study introduces AntiBMPNN, an advanced deep‐learning framework that leverages an antibody‐specific 3D dataset, a fine‐tuned message‐passing neural network (MPNN), a frequency‐based scoring function, and AlphaFold 3 to achieve highly accurate antibody sequence design. AntiBMPNN surpasses ProteinMPNN with a perplexity of 1.5 and over 80% sequence recovery. Its scoring function, combined with AlphaFold 3, effectively prioritizes sequences based on structural recovery, positional stability, and biochemical or complex properties. Experimental validation highlights a 75% success rate in single‐point antibody design. AntiBMPNN consistently outperforms AbMPNN, AntiFold, and ProteinMPNN in designing complementarity determining regions (CDR) 1‐3, yielding stronger binding affinities. For CDR1 of huJ3 (anti‐HIV nanobody), it achieves a half maximal effective concentration (EC₅₀) of 9.2 nM (nanomolar), better than ProteinMPNN (135.2 nM) and AntiFold (59.3 nM), and comparable to AbMPNN (6.6 nM). For CDR2 of the D6 nanobody (targeting CD16), AntiBMPNN reaches 0.3 nM, outperforming AbMPNN (2.3 nM), AntiFold (0.7 nM), and ProteinMPNN (0.7 nM). In CDR3 of huJ3, it achieves 1.7 nM, surpassing AbMPNN (51.2 nM), with no detectable activity from AntiFold or ProteinMPNN. These findings confirm that AntiBMPNN‐designed sequences for J3 and D6 outperform the originals, highlighting its potential to improve therapeutic antibody design.

6 April 2026 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
MHMouxin Huang
Mouxin Huang
HLHe Liu
He Liu
JZJinwei Zhu
Jinwei Zhu
ZFZhiwei Feng
Zhiwei Feng
QOQin Ouyang
Qin Ouyang

27 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCCheng Cao
Cheng Cao
RWRun-Lin Wang
Run-Lin Wang
CGChen-Xin Guo
Chen-Xin Guo
XXXiao-Wei Xu
Xiao-Wei Xu
JWJia-Hui Wei
Jia-Hui Wei
YCYan Chen
Yan Chen
This study aimed to investigate the protective effects of the CB2R ligand compound COCA (N-(3-chloro-2-methylphenyl)-5-(4-hydroxyphenyl)-1,2-oxazole-3-carboxamide) against bleomycin (BLM)-induced pulmonary fibrosis in mice. Compound COCA was identified via AI-driven virtual screening from the ChEMBL database. Forty male C57BL/6J mice were randomly divided into five groups: control, model (BLM), low-dose COCA, high-dose COCA, and pirfenidone. Pulmonary fibrosis was induced by intratracheal BLM administration in the model and treatment groups. Pathological evaluation, ELISA, immunofluorescence, and Western blot were conducted.The results showed that COCA significantly alleviated BLM-induced inflammation and fibrosis. ELISA demonstrated decreased serum levels of TNF-α and IL-6 in the treated groups compared to the BLM group ( P < 0.01). Immunofluorescence indicated reduced expression of Col-I and Col-III in the treated groups ( P < 0.01). Western blot analysis revealed an upregulation of CB2R in the BLM group, and enhanced expressions of Nrf2 and Smad7 in the treated groups ( P < 0.01).In conclusion, AI-driven virtual screening enabled the identification of the CB2R ligand COCA, which binds to CB2R, activates the Nrf2/Smad7 pathway, downregulates related cytokines, and plays a therapeutic and protective role in pulmonary fibrosis.

1 January 2026 in Research
Verified
Journal Article
Open access
JYJiayi Yuan
Jiayi Yuan
XXXiaowei Xu
Xiaowei Xu
ZSZe-Yu Sun
Ze-Yu Sun
SZShan Zhu
Shan Zhu
CWChunyu Wei
Chunyu Wei
YXYing Xue
Ying Xue
Major histocompatibility complex class II (MHC-II) neoantigens play a critical role in immunotherapy, either as direct effectors or through their influence on CD8 + T cells. However, only a small fraction of tumor DNA mutations qualify as functional neoantigens, and current prediction tools suffer from limited accuracy, making the in vivo design of highly immunogenic neoantigens challenging. Here, we present EpiMII, a structure-aware graph neural network model for de novo design of MHC-II epitopes. By integrating 3-dimensional structural information through an inverse folding strategy, EpiMII generates mimotopes that preserve T cell specificity while enhancing MHC-II binding affinity and immunogenicity. The model was trained on a first-of-its-kind curated dataset of 142,934 homology-modeled MHC-II epitope structures, overcoming the scarcity of experimentally resolved MHC-II–peptide complexes. Benchmarking analyses illustrate that EpiMII achieves a sequence recovery rate of 66.7% on a held-out test set and 79.0% on crystallized epitopes, markedly outperforming existing tools like ProteinMPNN. In a hepatocellular carcinoma case study, all 5 EpiMII-designed epitopes could markedly activate CD4 + T cells in vitro and induce the secretion of interferon-γ and tumor necrosis factor-α. Notably, treatment with one epitope (P4) substantially reduced tumor volume in mice in vivo, comparable to a known positive control. These findings establish EpiMII as a powerful tool for structure-guided neoantigen discovery, with broad implications for cancer vaccine development and personalized immunotherapy.